Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 3/2024

Inhalt (20 Artikel)

Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning

  • Open Access
  • Research

Zhen Kang, Yu-Xuan Zhao, Ren Shun Qian Qiu, Dong-Ning Chen, Qing-Shui Zheng, Xue-Yi Xue, Ning Xu, Yong Wei

Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment

  • Open Access
  • Research

Toru Hanamura, Kozue Yokoyama, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi, Jennifer K. Richer, Naoki Niikura

Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells

  • Open Access
  • Research

Natthaporn Sueangoen, Harald Grove, Nisa Chuangchot, Jaturawitt Prasopsiri, Thanyada Rungrotmongkol, Kamonpan Sanachai, Nitchakan Darai, Suyanee Thongchot, Prapat Suriyaphol, Doonyapat Sa-Nguanraksa, Peti Thuwajit, Pa-thai Yenchitsomanus, Chanitra Thuwajit

INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors

  • Open Access
  • Research

John F. Hilton, Patrick A. Ott, Aaron R. Hansen, Zujun Li, Matthen Mathew, Cristina H. Messina, Vimal Dave, Xiao Ji, Natalie O. Karpinich, Steven Hirschfeld, Marc Ballas, Dan P. Zandberg

Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells

  • Open Access
  • Brief Report

Kathryn Kline, Tim Luetkens, Rima Koka, Michael E. Kallen, Wengen Chen, Haroon Ahmad, Destiny Omili, Thierry Iraguha, Etse Gebru, Xiaoxuan Fan, Alexis Miller, Nishanthini Dishanthan, Jillian M. Baker, Kenneth A. Dietze, Kim G. Hankey, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Saurabh Dahiya, Djordje Atanackovic

Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes

  • Open Access
  • Research

Konstantinos Ntostoglou, Sofia D. P. Theodorou, Tanja Proctor, Ilias P. Nikas, Sinclair Awounvo, Athanasia Sepsa, Vassilis Georgoulias, Han Suk Ryu, Ioannis S. Pateras, Christos Kittas

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients

  • Open Access
  • Research

Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiaohong Han, Yuankai Shi

Targeting monoamine oxidase A: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators

  • Open Access
  • Review

Yifan Ma, Hanmu Chen, Hui Li, Zhite Zhao, Qingling An, Changhong Shi

Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma

  • Open Access
  • Research

Anan Chen, Zhiwu Yu, Na Ma, Xinyu Lu, Yajing Zhang, Weikang Xu, Yiyue Wang, Jiayi Xie, Yuqi Qin, Guoheng Mo, Sha Wu, Jinlin Hou, Wei Zhu

Low-intensity pulsed ultrasound activated the anti-tumor immunity by irradiating the spleen of mice in 4 T-1 breast cancer

  • Open Access
  • Research

Yi Xia, Meijie Yang, Xinfang Xiao, Wentao Tang, Juan Deng, Liu Wu, Haopeng Xu, Yilin Tang, Wenzhi Chen, Yan Wang

Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade

  • Open Access
  • Research

Sweta Karan, Eunkyeong Jung, Christine Boone, Nicole F. Steinmetz

Targeting metabolic sensing switch GPR84 on macrophages for cancer immunotherapy

  • Open Access
  • Research

Jianying Li, Anjun Ma, Ruohan Zhang, Yao Chen, Chelsea Bolyard, Bao Zhao, Cankun Wang, Thera Pich, Wantong Li, Nuo Sun, Qin Ma, Haitao Wen, Steven K. Clinton, William E. Carson III, Zihai Li, Gang Xin

Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility

  • Open Access
  • Review

M. De Silva, B. C. Y. Tse, C. I. Diakos, S. Clarke, M. P. Molloy

Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization

  • Open Access
  • Research

Wenxin Xu, Jialei Weng, Minghao Xu, Qiang Zhou, Shaoqing Liu, Zhiqiu Hu, Ning Ren, Chenhao Zhou, Yinghao Shen

Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer

  • Open Access
  • Research

Angisha Basnet, Kaitlyn M. Landreth, Remi Nohoesu, Stell P. Santiago, Werner J. Geldenhuys, Brian A. Boone, Tracy W. Liu

Granzyme B+ B cells detected by single-cell sequencing are associated with prognosis in patients with intrahepatic cholangiocarcinoma following liver transplantation

  • Open Access
  • Research

Ji-Qiao Zhu, Ying Zhu, Man Qi, Ye Zeng, Zhen-Jia Liu, Cheng Ding, Tao Zhang, Xian-Liang Li, Dong-Dong Han, Qiang He

Multiplexed analysis of macrophage polarisation in pulmonary metastases of microsatellite stable colorectal cancer

  • Open Access
  • Research

Topias Karjula, Hanna Elomaa, Sara A. Väyrynen, Teijo Kuopio, Maarit Ahtiainen, Olli Mustonen, Iiris Puro, Anne Niskakangas, Jukka-Pekka Mecklin, Jan Böhm, Erkki-Ville Wirta, Toni T. Seppälä, Eero Sihvo, Fredrik Yannopoulos, Olli Helminen, Juha P. Väyrynen

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

  • Open Access
  • Research

Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan, Daniel J Chin, Su-Yi Tseng, Scott L Klakamp, Kate Widmann, Varun N Kapoor, Vladimir Vexler, Patricia Keegan, Sheng Yao, Theresa LaVallee, Sanjay D Khare

Neu im Fachgebiet Onkologie

Nach kardiovaskulärer Erkrankung steigt das Krebsrisiko

Wer an einer kardiovaskulären Erkrankung (CVD) leidet, hat offenbar ein erhöhtes Risiko, in der Folge auch noch eine Krebsdiagnose zu erhalten. Der Zusammenhang scheint für diverse CVD und Krebsentitäten zu gelten.

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu spezifischer CAR-T-Zell-Therapie bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.